A7805612
Vonoprazan Fumarate (TAK-438) , ≥98% , 1260141-27-2
CAS NO.：1260141-27-2
Empirical Formula: C21H20FN3O6S
Molecular Weight: 461.463
MDL number: MFCD18633280
EINECS: 250-635-4
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB23.20 | In Stock |
|
| 25MG | RMB71.20 | In Stock |
|
| 100MG | RMB188.80 | In Stock |
|
| 500mg | RMB799.20 | In Stock |
|
| 1G | RMB1142.40 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| storage temp. | Store at -20°C |
| solubility | insoluble in H2O; insoluble in EtOH; ≥18.9 mg/mL in DMSO |
| form | solid |
| InChIKey | ROGSHYHKHPCCJW-WLHGVMLRSA-N |
| SMILES | N1(S(C2=CC=CN=C2)(=O)=O)C(C2=CC=CC=C2F)=CC(CNC)=C1.C(O)(=O)/C=C/C(O)=O |
Description and Uses
Vonoprazan fumarate (Takecab), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis.
Vonoprazan Fumarate is a novel potassium-competitive acid blocker for the treatment of acid-related diseases.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501 |
